Spots Global Cancer Trial Database for Potential Drug Interaction Between ALXN2040 and Rosuvastatin

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Potential Drug Interaction Between ALXN2040 and Rosuvastatin

Official Title: A Phase 1 Study to Evaluate the Potential Drug Interaction Between ALXN2040 and Rosuvastatin in Healthy Adult Participants

Study ID: NCT05708573

Conditions

Healthy Participants

Interventions

Rosuvastatin

ALXN2040

Study Description

Brief Summary: This study will assess the potential drug-drug interaction (DDI) between ALXN2040 and rosuvastatin.

Detailed Description: This is an open-label, 2-treatment, 2-period, fixed-sequence DDI study in healthy adult participants. This study will comprise of: * Screening duration of 27 days. * Two treatment periods: Approximately 14 days. Treatment Period 1: 6 days Treatment Period 2: 8 days * Follow-up: 7 (± 2) days following the final dose of study intervention. There will be a washout period of at least 5 days between the single dose of rosuvastatin in Treatment Period 1 and the first dose of ALXN2040 in Treatment Period 2. Each participant will be involved in the study for approximately 48 days.